8-K: Keros Therapeutics Halts Dosing in Higher Arms of Phase 2 PAH Trial Due to Safety Concerns

Keros Therapeutics has voluntarily paused dosing in the 3.0 mg/kg and 4.5 mg/kg arms of its Phase 2 TROPOS trial for pulmonary arterial hypertension due to unexpected safety issues.

Summary

• Keros Therapeutics has stopped dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of the TROPOS trial, a Phase 2 study of cibotercept for pulmonary arterial hypertension (PAH).
• This decision was made following a safety review that revealed unanticipated pericardial effusion adverse events.
• The 1.5 mg/kg treatment arm of the trial will continue dosing after a risk and benefit assessment by the independent Data Monitoring Committee (DMC).
• The company is working with investigators, the FDA, and other regulatory authorities to address the safety concerns.
• Keros still plans to present topline data from all treatment arms in the second quarter of 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the safety concerns and the halt of dosing in the higher arms of the trial, which could impact the drug's development and the company's valuation.

Positives

• The company is prioritizing patient safety by halting dosing in the affected arms.
• The 1.5 mg/kg treatment arm continues, allowing for further data collection.
• Keros is working with regulatory authorities to address the issue.
• The company still expects to present topline data in the second quarter of 2025.

Negatives

• The halt in dosing in the higher dose arms is due to unanticipated safety issues.
• Pericardial effusion adverse events were observed, raising concerns about the drug's safety profile.
• The company will need to investigate and address the safety concerns, which may delay the trial.

Risks

• The unanticipated safety issues could impact the development timeline of cibotercept.
• Regulatory authorities may require additional safety studies or changes to the trial protocol.
• The company's ability to raise additional funding could be affected by the safety concerns.
• There is a risk that the final results of the trial may not be positive.

Future Outlook

Keros expects to present topline data from all treatment arms of the TROPOS trial in the second quarter of 2025, and will provide updates as they become available.

Management Comments

• Jasbir S. Seehra, Ph.D., Chair and CEO, stated that patient safety is the top priority.
• Management is working diligently to understand the unanticipated findings and address them quickly.

Industry Context

This announcement highlights the inherent risks in clinical trials, particularly in the development of novel therapeutics for complex diseases like PAH. The pause in dosing reflects a commitment to patient safety, which is a key concern for regulatory bodies and investors in the biopharmaceutical industry.

Comparison to Industry Standards

• The voluntary halt of dosing due to safety concerns is consistent with industry best practices for clinical trials.
• Other companies developing treatments for PAH, such as United Therapeutics and Acceleron Pharma, have also faced challenges in clinical development, including safety issues.
• The decision to continue dosing in the lower dose arm while investigating the safety concerns is a common approach in clinical trials to balance patient safety with the need to gather data.

Stakeholder Impact

• Shareholders may be concerned about the potential impact of the safety issues on the company's valuation.
• Patients in the trial may be affected by the halt in dosing, but patient safety is the priority.
• Employees may be impacted by the changes in the trial timeline.
• Regulatory authorities will be closely monitoring the situation.

Next Steps

• Keros will work with investigators, the FDA, and other regulatory authorities to address the safety concerns.
• The company will continue safety and efficacy data collection for all treatment arms.
• Keros will investigate the cause of the pericardial effusion adverse events.
• The company will provide additional information when there is a material update.
• Keros will present topline data from all treatment arms in the second quarter of 2025.

Key Dates

Keywords

Keros Therapeutics, cibotercept, pulmonary arterial hypertension, PAH, TROPOS trial, clinical trial, pericardial effusion, safety, FDA, Data Monitoring Committee